Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

Mary Choy, PharmD, BCGP, FASHP |
Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.
Will Boggs, MD |
NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC). “The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells…
Reuters Staff |
NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to…
According to new research, women with SLE are at the highest risk for adverse pregnancy outcomes during a lupus flare. The data may enable clinicians to use risk stratification and tailored monitoring to counsel SLE patients who are pregnant or considering pregnancy. Researchers also found that maternal age, lupus nephritis and antiphospholipid antibodies may affect pregnancy outcomes…
Reuters Staff |
NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in…
In Europe, researchers are evaluating the safety, tolerability and efficacy of ABX464 in rheumatoid arthritis patients…
Sir William Osler, widely regarded as one of the greatest physicians of the 20th century, once said, “He who studies medicine without books sails an uncharted sea, but he who studies medicine without patients does not go to sea at all.”1 This sentiment is particularly true in the field of rheumatology, in which understanding the…
Funck-Brentano et al. hypothesized that causal associations for osteoarthritis (OA) may differ by site, and they undertook this study to identify causal risk factors of knee, hip and hand OA.
Reuters Staff |
NEW YORK (Reuters Health)—Anti-tumor necrosis factor (TNF) treatment is associated with a reduced risk of acute arterial events in patients with inflammatory bowel disease (IBD), especially men, new research shows. IBD patients face an increased risk of acute arterial events, which are also independently associated with disease activity, Julien Kirchgesner, MD, PhD, of Hospital Saint-Antoine,…
Linda Carroll |
(Reuters Health)—More than 70% of healthcare data breaches in the U.S. have involved sensitive demographic or financial information that could fuel identity theft, a new study suggests. When a healthcare company is hacked, criminals gain access not only to health information, but also to demographic and financial data that could compromise patients’ privacy and financial…